Moderna announces detailed Phase 3 INTerpath-001 trial results as stock falls 1.4%

Traders Union
All News
Business & Wealth
Companies
Moderna stock falls 1.4% to $200.1

Top Stories

Editors' Picks

Stocks

Crypto

Economics

Currencies

Commodities

Business & Wealth

Market Voices

Anton Kharitonov

24.10.2026

Moderna announces detailed Phase 3 INTerpath-001 trial results as stock falls 1.4% — Moderna stock falls 1.4% to $200.1

Moderna announced detailed results from the Phase 3 INTerpath-001 trial of its investigational individualized neoantigen therapy in partnership with Merck. The stock is down 1.4% on the day at $200.1.

MRNA price prediction

24H 0.12%

$221.99

48H -0.04%

$221.64

7D -0.54%

$220.52

1M 6.88%

$236.97

3M 32.29%

$293.31

6M 114.46%

$475.5

12M 314.34%

$918.67

Current price: $221.72 -0.9700 0.44%

Closed 10/30

Daily range 217.50

227.44

Weekly range 179.72

227.44

Loading...

Highlights

Moderna and Merck revealed detailed Phase 3 INTerpath-001 results for their individualized neoantigen therapy in patients with resected disease.
19 of 92 analysts rate Moderna stock a buy versus 11 recommending a sell, with a median price target of $125.
Moderna stock is down 1.4% on the day at $200.1.

Moderna, in collaboration with Merck, announced detailed results from the Phase 3 INTerpath-001 trial assessing the investigational individualized neoantigen therapy intismeran autogene (mRNA-4157 or V940) alongside pembrolizumab in patients with completely resected disease. The update was released directly by the company. The event was announced on October 22, 2026, according to Yahoo! Finance.

View post on X Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Range compression as oversold signals limit further downside

The session opened with a gap down from the previous close of $203.1 to $196.14, and price has since given part of that move back. Shares of Moderna are currently trading below the MA-20 but remain above the MA-50 and MA-200, reflecting a split daily structure. The nearest resistance is the Ichimoku Kijun at $203.81. Stoch RSI is in oversold territory, a stretched reading that limits room for further downside and could support stabilization.

Upside odds lead for five days as traders eye $203.81 level

Traders should watch for a close above $203.81 to confirm buyers are willing to follow through. The stock opened sharply lower from $203.1 to $196.14 before recouping some of the initial drop. Despite a sustained move lower with a firm trend over the past week, the next five trading days carry a 62% probability of upside versus 38% for downside, with the expected trading range between $167.35 and $232.84. A drop below $180.94 would show the move is being faded. On the weekly chart the longer-term picture stays firmly constructive.

Previously it was reported that Moderna's shares were at a critical technical juncture following the announcement of positive Phase 3 results for its individualized neoantigen therapy in combination with Merck's KEYTRUDA. The current technical setup suggests traders should watch for stabilization above $203.81, with risks skewed toward volatility inside the $167.35–$232.84 range over the coming days.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Did you like the article?

#Moderna

Editor's Picks for You

By Olena Litvinenko
37 min ago

Not Satoshi: Who created Bitcoin’s logo?

Editors' Picks

Ryanair tightens its belt: How rising fuel prices threaten the budget airline

By Eugene Komchuk
4 hours ago

Ryanair tightens its belt: How rising fuel prices threaten the budget airline

Editors' Picks

How German metalworkers’ strikes are testing Europe’s industrial strength

By Dmytro Kharkov
6 hours ago

How German metalworkers’ strikes are testing Europe’s industrial strength

Editors' Picks

All Editors' Top Picks

Latest Moderna News

Moderna shares gain almost 4% after strong Phase 3 melanoma vaccine results and technical breakout

By Anton Kharitonov
28.10.2026

Moderna shares gain almost 4% after strong Phase 3 melanoma vaccine results and technical breakout

Stocks

#Forecast #Moderna

What's behind Moderna's latest 3.5% stock surge?

By Ivan Andriyenko
27.10.2026

What's behind Moderna's latest 3.5% stock surge?

Stocks

#Forecast #Moderna

Moderna announces detailed positive Phase 3 study results: Can MRNA break above $198.48?

By Mira Kyivska
22.10.2026

Moderna announces detailed positive Phase 3 study results: Can MRNA break above $198.48?

Companies

All Moderna News

Olena Litvinenko
37 min ago

Not Satoshi: Who created Bitcoin’s logo?

Eugene Komchuk
4 hours ago

Ryanair tightens its belt: How rising fuel prices threaten the budget airline

Dmytro Kharkov
6 hours ago

How German metalworkers’ strikes are testing Europe’s industrial strength

Pavlo Kot
Yesterday

DeFi for the select few: Why Hyperliquid is building restricted markets

Pavlo Kot
31.10.2026

Can Bitcoin make you a millionaire?

Oksana Koneva
5 min ago

Andy Constan: Deal spread implies 7.2% potential return versus 4.5% cash

Yulia Slavina
19 min ago

Francis Pouliot: Austria joins European opposition to DAC8 regulation

Ksenia Gerey
21 min ago

Leveraged long ETFs saw record $12 billion inflows, Eric Balchunas notes

Eugene Komchuk
24 min ago

Freddie Mac halts new lending while Fannie Mae factors in rent freeze costs, Jay Parsons notes

Daria Chernytska
26 min ago

Guy LeBas: Start of most consistently positive 3-month bond market stretch identified

Top News

Jose Antonio Gastelum
33 min ago

Morgan Stanley downgrades Coinbase and cuts price target by more than half

Morgan Stanley downgrades Coinbase and cuts price target by more than half

Hanna Syniavska
2 hours ago

SpaceX explores Boost Mobile deal to enter U.S. wireless market

SpaceX explores Boost Mobile deal to enter U.S. wireless market

Igor Krasulya
4 hours ago

Alphabet returns to euro bond market despite disappointing earnings

Alphabet returns to euro bond market despite disappointing earnings

Ivan Andriyenko
4 hours ago

Gold climbs above $3,900 as bargain hunters return after October rout

Gold climbs above $3,900 as bargain hunters return after October rout

Andrey Mastykin
5 hours ago

Anthropic taps Japanese investors ahead of major U.S. listing as AI financing expands

Anthropic taps Japanese investors ahead of major U.S. listing as AI financing expands

Top 5 companies for you

United States

Live News

Eugene Komchuk
Now

Binance hackers convert stolen Solana into Bitcoin

Andrey Mastykin
Now

Wall Street futures climb as investors await Apple earnings and U.S. elections

Mykhailo Ihnatenko
Now

AMD stock eyes $528 as earnings risk raises volatility

Anton Kharitonov
Now

EUR/USD struggles to sustain recovery as eurozone risks persist

Eugene Komchuk
Now

Hong Kong launches 24/7 settlement for tokenized assets

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.